Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company whose core business model involves the development of novel antibiotics. The company’s primary product candidates are designed to treat infections caused by multi-drug resistant pathogens, a process that requires extensive animal testing for regulatory approval and safety assessment. This reliance on animal models is inherent to its sector and central to its research and development pipeline.

The company’s operations fall under the general animal exploitation exclusion because its business is predicated on the commercial use of animals in biomedical research. While specific, publicly documented incidents of welfare violations at Iterum are not cited in the provided evidence, the firm’s foundational activity—developing pharmaceuticals through preclinical animal testing—constitutes commercial exploitation of animals at scale. This aligns with the exclusion category’s intent to capture exploitation not covered by more specific codes like animal testing for cosmetics or meat production.